Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reference-based pricing in Part D

Executive Summary

Beginning Dec. 23, CMS will add a footnote to more places in its Medicare Part D Plan Finder Web site alerting users that reference-based pricing may apply to the cost of certain brands, a spokesman said. Approximately 10 percent of the 2009 Part D contracts use the reference-based pricing, according to the agency. Reference-based pricing in Part D involves the requirement that, on top of a co-pay, members must pay an additional charge if they choose a brand-name drug when its generic equivalent is available 1("The Pink Sheet," Dec. 8, 2008, p. 21). AARP wrote to CMS Dec. 16 requesting changes to Plan Finder to ensure greater transparency on the practice and that beneficiaries who enrolled based on "misleading" information in Plan Finder be permitted to switch plans beyond the Dec. 31 enrollment deadline

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel